Search research articles
Contact Us
Filters
Showing results (71-80 of 193) with videos related to
Page
of 20
Sort By:
Antimicrobial Agents and Chemotherapy
|
March 7, 2018
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K Shields, M Hong Nguyen, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 1, 2017
<i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases
Ryan K Shields, M Hong Nguyen, Ellen G Press, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Allele-Specific Effects of Mutations in the Rifampin Resistance-Determining Region (RRDR) of RpoB on Physiology and Antibiotic Resistance in <i>Enterococcus faecium</i>
Adeline Supandy, Emma G Mills, Kyong T Fam, et al.
Antimicrobial Agents and Chemotherapy
|
June 5, 2019
Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model
G L Drusano, Ryan K Shields, Nino Mtchedlidze, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 25, 2024
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?
Samuel L Aitken, Virginia M Pierce, Jason M Pogue, et al.
Antimicrobial Agents and Chemotherapy
|
January 28, 2025
Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
Ava J Dorazio, Ellen G Kline, Kevin M Squires, et al.
Antimicrobial Agents and Chemotherapy
|
June 21, 2017
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
Ghady Haidar, Cornelius J Clancy, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy
|
November 9, 2016
Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure
Deanna J Buehrle, Ryan K Shields, Lloyd G Clarke, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion
Akito Kawai, Christi L McElheny, Alina Iovleva, et al.
Antibiotics (Basel, Switzerland)
|
February 27, 2026
Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies
Ignacio Martin-Loeches, Ryan K Shields, Emre Yücel, et al.
Page
of 20
Search research articles
Search
Showing results (71-80 of 193) with videos related to
Sort By:
Page
of 20
Antimicrobial Agents and Chemotherapy
|
March 7, 2018
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K Shields, M Hong Nguyen, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 1, 2017
<i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases
Ryan K Shields, M Hong Nguyen, Ellen G Press, et al.
Biorxiv : the Preprint Server for Biology
|
August 13, 2025
Allele-Specific Effects of Mutations in the Rifampin Resistance-Determining Region (RRDR) of RpoB on Physiology and Antibiotic Resistance in <i>Enterococcus faecium</i>
Adeline Supandy, Emma G Mills, Kyong T Fam, et al.
Antimicrobial Agents and Chemotherapy
|
June 5, 2019
Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of <i>Klebsiella pneumoniae</i> in a Hollow Fiber Infection Model
G L Drusano, Ryan K Shields, Nino Mtchedlidze, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 25, 2024
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?
Samuel L Aitken, Virginia M Pierce, Jason M Pogue, et al.
Antimicrobial Agents and Chemotherapy
|
January 28, 2025
Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
Ava J Dorazio, Ellen G Kline, Kevin M Squires, et al.
Antimicrobial Agents and Chemotherapy
|
June 21, 2017
Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
Ghady Haidar, Cornelius J Clancy, Liang Chen, et al.
Antimicrobial Agents and Chemotherapy
|
November 9, 2016
Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure
Deanna J Buehrle, Ryan K Shields, Lloyd G Clarke, et al.
Antimicrobial Agents and Chemotherapy
|
April 15, 2020
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion
Akito Kawai, Christi L McElheny, Alina Iovleva, et al.
Antibiotics (Basel, Switzerland)
|
February 27, 2026
Ceftolozane/Tazobactam for Complex and Resistant Infections: Systematic Reviews of Comparative Efficacy Studies
Ignacio Martin-Loeches, Ryan K Shields, Emre Yücel, et al.
Page
of 20